$BCDA
BioCardia, Inc. Stock $bcda

$bcda Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000143774922026591 Filed on November 09, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$106.0K	$212.0K	$821.0K
YoY Change	34.18%	-74.18%	2314.71%
Cost Of Revenue			$0.00
YoY Change
Gross Profit			$821.0K
YoY Change			2314.71%
Gross Profit Margin			100.0%
Selling, General & Admin	$924.0K	$1.128M	$1.289M
YoY Change	-35.16%	-12.49%	-8.45%
% of Gross Profit			157.0%
Research & Development	$2.200M	$2.144M	$2.240M
YoY Change	4.02%	-4.29%	-9.46%
% of Gross Profit			272.84%
Depreciation & Amortization	$21.00K	$29.00K	$15.00K
YoY Change	40.0%	93.33%	0.0%
% of Gross Profit			1.83%
Operating Expenses	$3.124M	$3.272M	$3.529M
YoY Change	-11.75%	-7.28%	-9.09%
Operating Profit		-$3.060M	-$2.708M
YoY Change		13.0%	-29.63%
Interest Expense			$2.000K
YoY Change			100.0%
% of Operating Profit
Other Income/Expense, Net	-$10.00K	$3.000K	$2.000K
YoY Change	900.0%	50.0%
Pretax Income	-$3.028M	-$3.057M	-$2.706M
YoY Change	-12.51%	12.97%	-29.71%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$3.028M	-$3.057M	-$2.706M
YoY Change	-12.51%	12.97%	-29.68%
Net Earnings / Revenue	-2856.6%	-1441.98%	-329.6%
Basic Earnings Per Share		-$0.17	-$0.16
Diluted Earnings Per Share	-$0.17	-$171.3K	-$158.6K
COMMON SHARES
Basic Shares Outstanding	17.84M	17.76M	16.87M
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.363M	$6.667M	$15.89M
YoY Change	-42.8%	-58.04%	114.99%
Cash & Equivalents	$7.400M	$6.667M	$15.90M
Short-Term Investments
Other Short-Term Assets	$300.0K	$187.0K	$358.0K
YoY Change	-35.06%	-47.77%	175.38%
Inventory
Prepaid Expenses
Receivables	$201.0K	$300.0K	$198.0K
Other Receivables	$0.00	$0.00	$562.0K
Total Short-Term Assets	$7.864M	$7.154M	$17.01M
YoY Change	-41.67%	-57.93%	97.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$170.0K	$189.0K	$175.0K
YoY Change	-6.59%	8.0%	8.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$171.0K	$172.0K	$0.00
YoY Change	-0.58%		-100.0%
Total Long-Term Assets	$1.929M	$2.025M	$324.0K
YoY Change	-13.77%	525.0%	-64.47%
TOTAL ASSETS
Total Short-Term Assets	$7.864M	$7.154M	$17.01M
Total Long-Term Assets	$1.929M	$2.025M	$324.0K
Total Assets	$9.793M	$9.179M	$17.33M
YoY Change	-37.7%	-47.03%	82.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$683.0K	$887.0K	$846.0K
YoY Change	34.71%	4.85%	-29.97%
Accrued Expenses	$157.0K	$115.0K	$79.00K
YoY Change	-34.58%	45.57%	-24.76%
Deferred Revenue	$341.0K	$378.0K	$886.0K
YoY Change	-59.74%	-57.34%	884.44%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.585M	$3.684M	$3.918M
YoY Change	-3.42%	-5.97%	-9.31%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$1.316M	$1.398M
YoY Change	-19.31%
Total Long-Term Liabilities	$1.316M	$1.398M	$0.00
YoY Change	-19.31%		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.585M	$3.684M	$3.918M
Total Long-Term Liabilities	$1.316M	$1.398M	$0.00
Total Liabilities	$4.901M	$5.082M	$3.918M
YoY Change	-8.27%	29.71%	-27.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$140.6M	-$137.6M	-$125.2M
YoY Change	9.25%	9.88%	10.71%
Common Stock	$20.00K	$18.00K	$17.00K
YoY Change	17.65%	5.88%	41.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.892M	$4.097M	$13.41M
YoY Change
Total Liabilities & Shareholders Equity	$9.793M	$9.179M	$17.33M
YoY Change	-37.7%	-47.03%	82.38%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$3.028M	-$3.057M	-$2.706M
YoY Change	-12.51%	12.97%	-29.68%
Depreciation, Depletion And Amortization	$21.00K	$29.00K	$15.00K
YoY Change	40.0%	93.33%	0.0%
Cash From Operating Activities	-$2.997M	-$2.006M	-$2.643M
YoY Change	0.74%	-24.1%	-26.58%
INVESTING ACTIVITIES
Capital Expenditures	$2.000K	-$14.00K	-$20.00K
YoY Change	-104.88%	-30.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$2.000K	-$14.00K	-$20.00K
YoY Change	-95.12%	-30.0%	0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.695M	73.00K	8.000K
YoY Change		812.5%	-111.43%
NET CHANGE
Cash From Operating Activities	-2.997M	-2.006M	-2.643M
Cash From Investing Activities	-2.000K	-14.00K	-20.00K
Cash From Financing Activities	3.695M	73.00K	8.000K
Net Change In Cash	696.0K	-1.947M	-2.655M
YoY Change	-123.08%	-26.67%	-28.05%
FREE CASH FLOW
Cash From Operating Activities	-$2.997M	-$2.006M	-$2.643M
Capital Expenditures	$2.000K	-$14.00K	-$20.00K
Free Cash Flow	-$2.999M	-$1.992M	-$2.623M
YoY Change	2.22%	-24.06%	-26.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	bcda	Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice	0
	bcda	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	-0
	bcda	Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice	-0
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0000925741
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0000925741
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0000925741
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0000925741
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0000925741
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	0-21419
	dei	Entity Registrant Name EntityRegistrantName	BioCardia, Inc
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	23-2753988
	dei	Entity Address Address Line1 EntityAddressAddressLine1	320 Soquel Way
	dei	Entity Address City Or Town EntityAddressCityOrTown	Sunnyvale
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94085
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	226-0120
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6667000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12872000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	13000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	22000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	300000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	147000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	187000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	462000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	7154000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	13481000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	189000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	182000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1664000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1883000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	172000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	172000	usd
CY2022Q3	us-gaap	Assets Assets	9179000	usd
CY2021Q4	us-gaap	Assets Assets	15718000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	887000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	507000	usd
CY2022Q3	bcda	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	2115000	usd
CY2021Q4	bcda	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	2121000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	378000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	847000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	304000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	237000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3684000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3712000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1398000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1631000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	5082000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	5343000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17841927
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17841927
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16871265
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16871265
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	18000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	17000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	141655000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	139055000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-137576000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-128697000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	4097000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9179000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15718000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	212000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	821000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1246000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	936000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2144000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2240000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6634000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6443000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1128000	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1289000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3495000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	416000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3662000	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	3272000	usd
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	3529000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	10129000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	10105000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3060000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2708000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8883000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9169000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3057000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2706000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9162000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17844991
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17066068
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17523837
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16867652
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	19176000	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	67000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1934000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	18562000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	384000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	214000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	437000	usd
CY2021Q3	bcda	Adjustments To Additional Paid In Capital Stock Issued Refund Of Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedRefundOfIssuanceCosts	8000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2706000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	13412000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10375000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	319000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3325000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	7369000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	271000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	232000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1287000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	304000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2497000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	6734000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	140000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	280000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3057000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	4097000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8879000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9162000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	61000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	45000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	219000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	418000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	903000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1237000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	153000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-34000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-275000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-97000	usd
	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	-0	usd
	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	-56000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	380000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	100000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	265000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	34000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-469000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	203000	usd
	bcda	Increase Decrease In Non Current Operating Lease Liability IncreaseDecreaseInNonCurrentOperatingLeaseLiability	-166000	usd
	bcda	Increase Decrease In Non Current Operating Lease Liability IncreaseDecreaseInNonCurrentOperatingLeaseLiability	-453000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7564000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7391000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	68000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	75000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-68000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-75000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1658000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2001000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	231000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	59000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1427000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1947000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6205000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5519000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12872000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21407000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6667000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15888000	usd
	bcda	Proceeds From Issuance Of Restricted Stock Units In Lieu Of Cash Bonus ProceedsFromIssuanceOfRestrictedStockUnitsInLieuOfCashBonus	401000	usd
	bcda	Proceeds From Issuance Of Restricted Stock Units In Lieu Of Cash Bonus ProceedsFromIssuanceOfRestrictedStockUnitsInLieuOfCashBonus	393000	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	137600000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6700000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>(c)</i></b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 18pt;"> </td> <td style="width: auto;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 18pt;"> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, right-of-use assets and related liabilities, incremental borrowing rate, allowances for doubtful accounts and sales returns, clinical accruals and assumptions used for revenue recognition.</p> </td> </tr> </tbody></table>
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	787000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	719000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	598000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	537000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	189000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	182000	usd
CY2021Q3	us-gaap	Depreciation Depreciation	15000	usd
	us-gaap	Depreciation Depreciation	45000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	121000	usd
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	362000	usd
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	150000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	451000	usd
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	114000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	287000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	162000	usd
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	486000	usd
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y4M2D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1074	pure
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.36
	bcda	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	0
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	114000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	471000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	485000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	499000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	514000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	44000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2127000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	425000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1702000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	115000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	240000	usd
CY2022Q3	bcda	Accrued Salaries And Employee Benefits Current AccruedSalariesAndEmployeeBenefitsCurrent	988000	usd
CY2021Q4	bcda	Accrued Salaries And Employee Benefits Current AccruedSalariesAndEmployeeBenefitsCurrent	861000	usd
CY2022Q3	bcda	Accured Clinical Trial Costs AccuredClinicalTrialCosts	352000	usd
CY2021Q4	bcda	Accured Clinical Trial Costs AccuredClinicalTrialCosts	334000	usd
CY2022Q3	bcda	Grant Liability Current GrantLiabilityCurrent	556000	usd
CY2021Q4	bcda	Grant Liability Current GrantLiabilityCurrent	590000	usd
CY2022Q3	bcda	Customer Deposit Liabilities Current CustomerDepositLiabilitiesCurrent	90000	usd
CY2021Q4	bcda	Customer Deposit Liabilities Current CustomerDepositLiabilitiesCurrent	96000	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	14000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	usd
CY2022Q3	bcda	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	2115000	usd
CY2021Q4	bcda	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	2121000	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2424724
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2424724
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.36
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	280000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	437000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	903000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1237000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1649686
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.00
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	603953
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.54
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	101796
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.77
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	3111
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	9.55
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2148732
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.08
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	248000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1052136
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.70
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y6M
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	22000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.49
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	2.72
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	1.49
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.81
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4576190
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4114258
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	14000	usd
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 27pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>(12)</b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Contingencies and Uncertainties</b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt; text-align: justify;"><i>Contingencies</i> - The Company may be subject to various claims, complaints, and legal actions that arise from time to time in the normal course of business. Management is not aware of any current legal or administrative proceedings that are likely to have an adverse effect on the Company’s business, financial position, results of operations, or cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 63pt;"><i>Uncertainties</i> - The results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other interim period or for any other future year, particularly in light of COVID-19 and its impact on domestic and global economies. Governmental and business reactions to the pandemic, and resulting economic disruptions, have the potential to materially impact our business and influence our business decisions. While the impact of COVID-19 did not have a material adverse effect on our financial position or results of operations for the periods presented, the Company’s future assessment of the magnitude and duration of COVID-19 and related factors, could result in material impacts to the Company’s financial statements in future reporting periods.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>

Files In Submission

Name	View Source	Status
0001437749-22-026591-index-headers.html	Edgar Link	pending
0001437749-22-026591-index.html	Edgar Link	pending
0001437749-22-026591.txt	Edgar Link	pending
0001437749-22-026591-xbrl.zip	Edgar Link	pending
bcda-20220930.xsd	Edgar Link	pending
bcda20220930_10q.htm	Edgar Link	pending
ex_439470.htm	Edgar Link	pending
ex_439471.htm	Edgar Link	pending
ex_439472.htm	Edgar Link	pending
ex_439473.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
bcda-20220930_lab.xml	Edgar Link	unprocessable
bcda-20220930_def.xml	Edgar Link	unprocessable
bcda-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bcda20220930_10q_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bcda-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCDA
BioCardia, Inc. Stock $bcda

2022 Q4 Form 10-Q Financial Statement

#000143774922026591 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCDA BioCardia, Inc. Stock $bcda

2022 Q4 Form 10-Q Financial Statement

#000143774922026591 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCDA
BioCardia, Inc. Stock $bcda